Seer, Inc. (SEER) AI Stock Analysis

Seer, Inc. is a life sciences company focused on commercializing products designed to analyze the proteome. Its primary offering is the Proteograph Product Suite, which integrates consumables, automated instrumentation, and software for proteomic studies. The company markets these solutions for non-diagnostic and non-clinical research applications, serving academic institutions, life sciences laboratories, and biopharmaceutical and biotechnology companies. Headquartered in Redwood City, California, Seer has established strategic collaborations with organizations such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies to support advancements in therapeutic, diagnostic, and clinical research.

Seer achieved a 5-year revenue CAGR of 89.7% from FY2020 to FY2025. Annual revenue expanded from $6.4M in FY2021 to $14.7M in FY2022 and $15.2M in FY2023, before declining 8.1% to $13.9M in FY2024. In FY2025, revenue grew 15.6% to $16.1M, with gross margin reaching 49.7% compared to -5.8% in FY2021. However, operating margin was -483.9% and net income was -$73.6M in FY2025. For the trailing twelve months ending June 30, 2026, revenue stood at $14.2M with an operating margin of -542.9% and diluted EPS of -$1.22, as quarterly revenue fell 23.4% year-over-year.

As of June 30, 2026, Seer reported $152.9M in cash and short-term investments against total debt of $22.4M, resulting in net cash of $130.5M. The company maintained a current ratio of 14.74 and a debt-to-equity ratio of 0.10, with shareholders' equity of $225.7M. In FY2025, operating cash flow was -$44.4M and free cash flow was -$46.2M. Capital expenditures totaled $1.8M and share buybacks were $10.2M for the year, contributing to a 5-year share count change of -10.4%.

Seer carries a market cap of $112.4M and an enterprise value of -$30.0M. The stock trades at a price-to-sales multiple of 7.9x, above the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA stands at 1.7x compared to the peer median of 12.0x, and its price-to-book ratio is 0.4x. As of October 16, 2026, the stock closed at $2.03, representing a 1-year return of -8.1% and a 5-year return of -93.8%, trailing the S&P 500 ETF returns of 16.8% and 83.0% over those same horizons.

Wall Street coverage comprises 2 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $4.00, representing an implied upside of 97.0% from the last close of $2.03. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $16.1M and an EPS of -$1.10. Over the last four quarters, the company delivered 1 EPS beat. The next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of Seer, Inc. (SEER). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SEER income statement, SEER balance sheet, SEER key metrics, SEER analyst forecast, SEER chart. See the SEER stock overview for the latest quote and news.